• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Risk factors for HCC in contemporary cohorts of patients with cirrhosis.肝硬化患者当代队列中 HCC 的风险因素。
Hepatology. 2023 Mar 1;77(3):997-1005. doi: 10.1002/hep.32434. Epub 2023 Feb 17.
2
Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001-2013.2001-2013 年美国退伍军人中潜在肝脏疾病导致的肝硬化和肝细胞癌负担趋势。
Gastroenterology. 2015 Nov;149(6):1471-1482.e5; quiz e17-8. doi: 10.1053/j.gastro.2015.07.056. Epub 2015 Aug 5.
3
Increasing liver stiffness is associated with higher incidence of hepatocellular carcinoma in hepatitis C infection and non-alcoholic fatty liver disease-A population-based study.在丙型肝炎感染和非酒精性脂肪性肝病患者中,肝硬度增加与肝细胞癌的发生率升高相关——一项基于人群的研究。
PLoS One. 2023 Jan 24;18(1):e0280647. doi: 10.1371/journal.pone.0280647. eCollection 2023.
4
Alcoholic liver disease confers a worse prognosis than HCV infection and non-alcoholic fatty liver disease among patients with cirrhosis: An observational study.一项观察性研究表明,在肝硬化患者中,酒精性肝病的预后比丙型肝炎病毒感染和非酒精性脂肪性肝病更差。
PLoS One. 2017 Oct 27;12(10):e0186715. doi: 10.1371/journal.pone.0186715. eCollection 2017.
5
Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease.非酒精性脂肪性肝病患者的肝细胞癌风险。
Gastroenterology. 2018 Dec;155(6):1828-1837.e2. doi: 10.1053/j.gastro.2018.08.024. Epub 2018 Aug 23.
6
Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease.比较丙型肝炎和非酒精性脂肪性肝病所致肝细胞癌的临床表现、治疗方法及预后。
QJM. 2017 Feb 1;110(2):73-81. doi: 10.1093/qjmed/hcw151.
7
Association of metabolic traits with occurrence of nonalcoholic fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis of longitudinal cohort studies.代谢特征与非酒精性脂肪性肝病相关肝细胞癌发生的关系:纵向队列研究的系统评价和荟萃分析。
Saudi J Gastroenterol. 2022 Mar-Apr;28(2):92-100. doi: 10.4103/sjg.sjg_260_21.
8
Non-alcoholic fatty liver disease is associated with greater risk of 30-day hospital readmission in the United States (U.S.).非酒精性脂肪性肝病与美国 30 天内再次住院的风险增加相关。
Ann Hepatol. 2023 Jul-Aug;28(4):101108. doi: 10.1016/j.aohep.2023.101108. Epub 2023 Apr 23.
9
Improved survival after treatments of patients with nonalcoholic fatty liver disease associated hepatocellular carcinoma.非酒精性脂肪性肝病相关肝细胞癌患者经治疗后生存率提高。
Sci Rep. 2020 Jun 18;10(1):9902. doi: 10.1038/s41598-020-66507-7.
10
Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification.用于风险分层的酒精或非酒精性脂肪性肝病相关肝硬化患者肝细胞癌风险的预测模型。
J Hepatol. 2019 Sep;71(3):523-533. doi: 10.1016/j.jhep.2019.05.008. Epub 2019 May 28.

引用本文的文献

1
Value of HCC surveillance in a landscape of emerging surveillance options: Perspectives of a multi-stakeholder modified Delphi panel.新兴监测选项背景下肝癌监测的价值:多利益相关方改良德尔菲小组的观点
Hepatology. 2025 Sep 1;82(3):794-809. doi: 10.1097/HEP.0000000000001203. Epub 2024 Dec 18.
2
Contemporary epidemiology of hepatocellular carcinoma: understanding risk factors and surveillance strategies.肝细胞癌的当代流行病学:了解风险因素和监测策略。
J Can Assoc Gastroenterol. 2024 Aug 9;7(5):331-345. doi: 10.1093/jcag/gwae025. eCollection 2024 Oct.
3
Non-parenchymal cells: key targets for modulating chronic liver diseases.非实质细胞:调节慢性肝病的关键靶点。
Front Immunol. 2025 Jun 11;16:1576739. doi: 10.3389/fimmu.2025.1576739. eCollection 2025.
4
Therapeutic Potential of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Liver Disease: Focus on Cirrhosis.钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂在肝脏疾病中的治疗潜力:聚焦于肝硬化
Cureus. 2025 May 25;17(5):e84768. doi: 10.7759/cureus.84768. eCollection 2025 May.
5
HCC surveillance in hepatitis C: A longitudinal algorithm improves alpha-fetoprotein screening.丙型肝炎中的肝细胞癌监测:一种纵向算法可改善甲胎蛋白筛查。
Hepatol Commun. 2025 May 23;9(6). doi: 10.1097/HC9.0000000000000719. eCollection 2025 Jun 1.
6
Characterisation of non-cirrhotic MAFLD-related hepatocellular carcinoma: a retrospective cohort study.非肝硬化性MAFLD相关肝细胞癌的特征:一项回顾性队列研究。
Ther Adv Chronic Dis. 2025 May 16;16:20406223251339402. doi: 10.1177/20406223251339402. eCollection 2025.
7
promotes lipid metabolism in hepatocellular carcinoma by regulating the signaling pathway through .通过……调节信号通路促进肝细胞癌中的脂质代谢。
Am J Transl Res. 2025 Apr 15;17(4):2527-2540. doi: 10.62347/ZTGP5030. eCollection 2025.
8
Patient-Perceived Risk of Hepatocellular Carcinoma and Net Benefit of Surveillance: A Multicenter Survey Study.患者对肝细胞癌的感知风险及监测的净效益:一项多中心调查研究
Am J Gastroenterol. 2025 Apr 23;120(8):1800-1808. doi: 10.14309/ajg.0000000000003494.
9
Shared genetic architecture of non-viral cirrhosis with several pleiotropic traits: A nested case-control study in the UK Biobank.非病毒性肝硬化与多种多效性性状的共享遗传结构:英国生物银行的一项巢式病例对照研究。
Liver Int Commun. 2024 Dec;5(4). doi: 10.1002/lci2.70002. Epub 2024 Nov 15.
10
Cost-effectiveness of an outreach program for HCC screening in patients with cirrhosis: a microsimulation modeling study.一项针对肝硬化患者肝癌筛查的外展项目的成本效益:一项微观模拟建模研究。
EClinicalMedicine. 2025 Feb 17;81:103113. doi: 10.1016/j.eclinm.2025.103113. eCollection 2025 Mar.

肝硬化患者当代队列中 HCC 的风险因素。

Risk factors for HCC in contemporary cohorts of patients with cirrhosis.

机构信息

Sections of Gastroenterology and Hepatology , Baylor College of Medicine , Houston , Texas , USA.

Health Services Research, Department of Medicine , Baylor College of Medicine , Houston , Texas , USA.

出版信息

Hepatology. 2023 Mar 1;77(3):997-1005. doi: 10.1002/hep.32434. Epub 2023 Feb 17.

DOI:10.1002/hep.32434
PMID:35229329
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9433461/
Abstract

BACKGROUND AND AIMS

Etiological risk factors for cirrhosis have changed in the last decade. It remains unclear to what extent these trends in cirrhosis risk factors have changed HCC risk.

APPROACH AND RESULTS

We used data from two contemporary, prospective multiethnic cohorts of patients with cirrhosis: the Texas Hepatocellular Carcinoma Consortium Cohort and the Houston Veterans Administration Cirrhosis Surveillance Cohort. Patients with cirrhosis were enrolled from seven US centers and followed until HCC diagnosis, transplant, death, or June 30, 2021. We calculated the annual incidence rates for HCC and examined the effects of etiology, demographic, clinical, and lifestyle factors on the risk of HCC. We included 2733 patients with cirrhosis (mean age 60.1 years, 31.3% women). At enrollment, 19.0% had active HCV, 23.3% had cured HCV, 16.1% had alcoholic liver disease, and 30.1% had NAFLD. During 7406 person-years of follow-up, 135 patients developed HCC at an annual incidence rate of 1.82% (95% CI, 1.51-2.13). The annual HCC incidence rate was 1.71% in patients with cured HCV, 1.32% in patients with alcoholic liver disease, and 1.24% in patients with NAFLD cirrhosis. Compared to patients with NAFLD, the risk of progression to HCC was 2-fold higher in patients with cured HCV (HR, 2.04; 95% CI, 1.24-3.35). Current smoking (HR, 1.63; 95% CI, 1.01-2.63) and overweight/obesity (HR, 1.79; 95% CI, 1.08-2.95) were also associated with HCC risk.

CONCLUSIONS

HCC incidence among patients with cirrhosis was lower than previously reported. HCC risk was variable across etiologies, with higher risk in patients with HCV cirrhosis and lower risk in those with NAFLD cirrhosis. Current smoking and overweight/obesity increased HCC risk across etiologies.

摘要

背景与目的

在过去的十年中,肝硬化的病因危险因素发生了变化。目前尚不清楚这些肝硬化危险因素的变化在多大程度上改变了 HCC 的风险。

方法和结果

我们使用了来自两个当代、前瞻性的多民族肝硬化患者队列的数据:德克萨斯州肝细胞癌联盟队列和休斯顿退伍军人事务局肝硬化监测队列。来自美国七个中心的患者被纳入研究,并随访至 HCC 诊断、移植、死亡或 2021 年 6 月 30 日。我们计算了 HCC 的年发生率,并研究了病因、人口统计学、临床和生活方式因素对 HCC 风险的影响。我们纳入了 2733 例肝硬化患者(平均年龄 60.1 岁,31.3%为女性)。在入组时,19.0%的患者有活动性 HCV,23.3%的患者 HCV 已治愈,16.1%的患者有酒精性肝病,30.1%的患者有非酒精性脂肪性肝病。在 7406 人年的随访期间,135 例患者发生 HCC,年发生率为 1.82%(95%CI,1.51-2.13)。在 HCV 已治愈的患者中,HCC 的年发生率为 1.71%,在酒精性肝病患者中为 1.32%,在非酒精性脂肪性肝病肝硬化患者中为 1.24%。与非酒精性脂肪性肝病患者相比,HCV 已治愈患者进展为 HCC 的风险增加了 2 倍(HR,2.04;95%CI,1.24-3.35)。目前吸烟(HR,1.63;95%CI,1.01-2.63)和超重/肥胖(HR,1.79;95%CI,1.08-2.95)也与 HCC 风险相关。

结论

肝硬化患者 HCC 的发病率低于之前的报道。HCC 的风险因病因而异,HCV 肝硬化患者的风险较高,而非酒精性脂肪性肝病肝硬化患者的风险较低。目前吸烟和超重/肥胖增加了各病因 HCC 的风险。